FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094250383> ?p ?o ?g. }

• W2094250383 endingPage "e28862" @default.
• W2094250383 startingPage "e28862" @default.
• W2094250383 abstract "The fluoropyrimidines 5-fluorouracil (5-FU) and FdUrd (5-fluorodeoxyuridine; floxuridine) are the backbone of chemotherapy regimens for colon cancer and other tumors. Despite their widespread use, it remains unclear how these agents kill tumor cells. Here, we have analyzed the checkpoint and DNA repair pathways that affect colon tumor responses to 5-FU and FdUrd. These studies demonstrate that both FdUrd and 5-FU activate the ATR and ATM checkpoint signaling pathways, indicating that they cause genotoxic damage. Notably, however, depletion of ATM or ATR does not sensitize colon cancer cells to 5-FU, whereas these checkpoint pathways promote the survival of cells treated with FdUrd, suggesting that FdUrd exerts cytotoxicity by disrupting DNA replication and/or inducing DNA damage, whereas 5-FU does not. We also found that disabling the base excision (BER) repair pathway by depleting XRCC1 or APE1 sensitized colon cancer cells to FdUrd but not 5-FU. Consistent with a role for the BER pathway, we show that small molecule poly(ADP-ribose) polymerase 1/2 (PARP) inhibitors, AZD2281 and ABT-888, remarkably sensitized both mismatch repair (MMR)-proficient and -deficient colon cancer cell lines to FdUrd but not to 5-FU. Taken together, these studies demonstrate that the roles of genotoxin-induced checkpoint signaling and DNA repair differ significantly for these agents and also suggest a novel approach to colon cancer therapy in which FdUrd is combined with a small molecule PARP inhibitor." @default.
• W2094250383 created "2016-06-24" @default.
• W2094250383 creator A5008210197 @default.
• W2094250383 creator A5011271236 @default.
• W2094250383 creator A5030736588 @default.
• W2094250383 creator A5048801471 @default.
• W2094250383 creator A5081855159 @default.
• W2094250383 date "2011-12-15" @default.
• W2094250383 modified "2023-10-18" @default.
• W2094250383 title "Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil" @default.
• W2094250383 cites W1611419331 @default.
• W2094250383 cites W1970195025 @default.
• W2094250383 cites W1972411998 @default.
• W2094250383 cites W1974788629 @default.
• W2094250383 cites W1978006133 @default.
• W2094250383 cites W1982787267 @default.
• W2094250383 cites W1983745036 @default.
• W2094250383 cites W1983811214 @default.
• W2094250383 cites W1984328540 @default.
• W2094250383 cites W1984926115 @default.
• W2094250383 cites W1987145875 @default.
• W2094250383 cites W1990133999 @default.
• W2094250383 cites W1990319096 @default.
• W2094250383 cites W1991658194 @default.
• W2094250383 cites W1998503027 @default.
• W2094250383 cites W1998790805 @default.
• W2094250383 cites W1999659306 @default.
• W2094250383 cites W2001633439 @default.
• W2094250383 cites W2002472122 @default.
• W2094250383 cites W2004122039 @default.
• W2094250383 cites W2012139546 @default.
• W2094250383 cites W2014123568 @default.
• W2094250383 cites W2020679229 @default.
• W2094250383 cites W2031866687 @default.
• W2094250383 cites W2033462866 @default.
• W2094250383 cites W2040617225 @default.
• W2094250383 cites W2045885851 @default.
• W2094250383 cites W2047383934 @default.
• W2094250383 cites W2049572301 @default.
• W2094250383 cites W2050293032 @default.
• W2094250383 cites W2052983658 @default.
• W2094250383 cites W2061686953 @default.
• W2094250383 cites W2066065452 @default.
• W2094250383 cites W2068359474 @default.
• W2094250383 cites W2074155500 @default.
• W2094250383 cites W2075486271 @default.
• W2094250383 cites W2083756299 @default.
• W2094250383 cites W2084203125 @default.
• W2094250383 cites W2086038769 @default.
• W2094250383 cites W2093961234 @default.
• W2094250383 cites W2094390470 @default.
• W2094250383 cites W2094584958 @default.
• W2094250383 cites W2096303088 @default.
• W2094250383 cites W2096588719 @default.
• W2094250383 cites W2097932770 @default.
• W2094250383 cites W2098457059 @default.
• W2094250383 cites W2099917396 @default.
• W2094250383 cites W2101988823 @default.
• W2094250383 cites W2107933236 @default.
• W2094250383 cites W2110017381 @default.
• W2094250383 cites W2113619479 @default.
• W2094250383 cites W2114105734 @default.
• W2094250383 cites W2115512932 @default.
• W2094250383 cites W2116005493 @default.
• W2094250383 cites W2119005391 @default.
• W2094250383 cites W2123696077 @default.
• W2094250383 cites W2125725576 @default.
• W2094250383 cites W2126583326 @default.
• W2094250383 cites W2128252882 @default.
• W2094250383 cites W2129237375 @default.
• W2094250383 cites W2130544215 @default.
• W2094250383 cites W2131670056 @default.
• W2094250383 cites W2135340562 @default.
• W2094250383 cites W2138693646 @default.
• W2094250383 cites W2139068229 @default.
• W2094250383 cites W2143037829 @default.
• W2094250383 cites W2144375658 @default.
• W2094250383 cites W2146435259 @default.
• W2094250383 cites W2146829486 @default.
• W2094250383 cites W2150598343 @default.
• W2094250383 cites W2150625137 @default.
• W2094250383 cites W2153812820 @default.
• W2094250383 cites W2154041044 @default.
• W2094250383 cites W2154482160 @default.
• W2094250383 cites W2162250864 @default.
• W2094250383 cites W2163168572 @default.
• W2094250383 cites W2167197605 @default.
• W2094250383 cites W2168953464 @default.
• W2094250383 cites W2171972386 @default.
• W2094250383 cites W3093265161 @default.
• W2094250383 cites W4249747365 @default.
• W2094250383 doi "https://doi.org/10.1371/journal.pone.0028862" @default.
• W2094250383 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3240632" @default.
• W2094250383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22194930" @default.
• W2094250383 hasPublicationYear "2011" @default.
• W2094250383 type Work @default.
• W2094250383 sameAs 2094250383 @default.
• W2094250383 citedByCount "32" @default.

• next